“Translational evidence for RRM2 as a prognostic biomarker and therapeutic target in Ewing sarcoma” study used Anti-RRM2 polyclonal antibody
March, 2021 (Hopp Children’s Cancer Center Heidelberg, Germany)
Ewing’s sarcoma is a rare cancerous tumor that grows in the bones and in the soft tissue around the bones, such as cartilage or the nerves. It mostly affects children, adolescents, and young adults.
In this study, our anti-RRM2 polyclonal antibody (HPA056994) provides translational evidence for RRM2 as a prognostic biomarker and therapeutic target in Ewing sarcoma.